XML 112 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Disclosures (Tables)
3 Months Ended
Feb. 29, 2020
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Accounted for at Fair Value on Recurring Basis
The following is a summary of our financial assets and liabilities that are accounted for at fair value on a recurring basis, excluding Investments at fair value based on net asset value (“NAV”) of $890.1 million and $570.3 million at February 29, 2020 and November 30, 2019, respectively, by level within the fair value hierarchy (in thousands):
 
February 29, 2020
 
Level 1
 
Level 2
 
Level 3
 
Counterparty and
Cash Collateral
Netting (1)
 
Total
Assets:
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
3,343,000

 
$
157,818

 
$
103,643

 
$

 
$
3,604,461

Corporate debt securities

 
2,841,022

 
25,090

 

 
2,866,112

Collateralized debt obligations and collateralized loan obligations

 
97,325

 
20,952

 

 
118,277

U.S. government and federal agency securities
1,541,590

 
98,176

 

 

 
1,639,766

Municipal securities

 
775,960

 

 

 
775,960

Sovereign obligations
1,552,798

 
1,194,447

 

 

 
2,747,245

Residential mortgage-backed securities

 
1,080,695

 
16,970

 

 
1,097,665

Commercial mortgage-backed securities

 
441,669

 
4,264

 

 
445,933

Other asset-backed securities

 
260,009

 
41,903

 

 
301,912

Loans and other receivables

 
2,651,109

 
54,321

 

 
2,705,430

Derivatives
864

 
3,290,943

 
23,244

 
(2,717,442
)
 
597,609

Investments at fair value

 
51,609

 
55,270

 

 
106,879

Total financial instruments owned, excluding Investments at fair value based on NAV
$
6,438,252

 
$
12,940,782

 
$
345,657

 
$
(2,717,442
)
 
$
17,007,249

Securities received as collateral
$
15,004

 
$

 
$

 
$

 
$
15,004

 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
2,124,882

 
$
2,897

 
$
4,275

 
$

 
$
2,132,054

Corporate debt securities

 
1,772,490

 
767

 

 
1,773,257

U.S. government and federal agency securities
1,577,052

 

 

 

 
1,577,052

Sovereign obligations
1,070,355

 
808,136

 

 

 
1,878,491

Commercial mortgage-backed securities

 

 
35

 

 
35

Loans

 
1,813,027

 
7,859

 

 
1,820,886

Derivatives
37

 
3,410,455

 
134,087

 
(2,849,172
)
 
695,407

Total financial instruments sold, not yet purchased
$
4,772,326

 
$
7,807,005

 
$
147,023

 
$
(2,849,172
)
 
$
9,877,182

Short-term borrowings
$

 
$
20,164

 
$

 
$

 
$
20,164

Obligation to return securities received as collateral
$
15,004

 
$

 
$

 
$

 
$
15,004

Long-term debt
$

 
$
811,251

 
$
543,463

 
$

 
$
1,354,714

(1)
Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
 
November 30, 2019
 
Level 1
 
Level 2
 
Level 3
 
Counterparty and
Cash Collateral
Netting (1)
 
Total
Assets:
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
2,325,116

 
$
218,403

 
$
58,301

 
$

 
$
2,601,820

Corporate debt securities

 
2,472,213

 
7,490

 

 
2,479,703

Collateralized debt obligations and collateralized loan obligations

 
124,225

 
20,081

 

 
144,306

U.S. government and federal agency securities
2,101,624

 
158,618

 

 

 
2,260,242

Municipal securities

 
742,326

 

 

 
742,326

Sovereign obligations
1,330,026

 
1,405,827

 

 

 
2,735,853

Residential mortgage-backed securities

 
1,069,066

 
17,740

 

 
1,086,806

Commercial mortgage-backed securities

 
424,060

 
6,110

 

 
430,170

Other asset-backed securities

 
303,847

 
42,563

 

 
346,410

Loans and other receivables

 
2,395,211

 
64,240

 

 
2,459,451

Derivatives
2,809

 
1,812,659

 
14,889

 
(1,432,806
)
 
397,551

Investments at fair value

 
32,688

 
75,738

 

 
108,426

Total financial instruments owned, excluding Investments at fair value based on NAV
$
5,759,575

 
$
11,159,143

 
$
307,152

 
$
(1,432,806
)
 
$
15,793,064

Securities purchased under agreements to resell
$

 
$

 
$
25,000

 
$

 
$
25,000

Securities received as collateral
$
9,500

 
$

 
$

 
$

 
$
9,500

 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
2,755,601

 
$
7,438

 
$
4,487

 
$

 
$
2,767,526

Corporate debt securities

 
1,471,142

 
340

 

 
1,471,482

U.S. government and federal agency securities
1,851,981

 

 

 

 
1,851,981

Sovereign obligations
1,363,475

 
941,065

 

 

 
2,304,540

Commercial mortgage-backed securities

 

 
35

 

 
35

Loans

 
1,600,228

 
9,463

 

 
1,609,691

Derivatives
871

 
2,066,064

 
92,057

 
(1,631,787
)
 
527,205

Total financial instruments sold, not yet purchased
$
5,971,928

 
$
6,085,937

 
$
106,382

 
$
(1,631,787
)
 
$
10,532,460

Short-term borrowings
$

 
$
20,981

 
$

 
$

 
$
20,981

Obligation to return securities received as collateral
$
9,500

 
$

 
$

 
$

 
$
9,500

Long-term debt
$

 
$
735,216

 
$
480,069

 
$

 
$
1,215,285

(1)
Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
Investments Measured at Fair Value Based on Net Asset Value Per Share
The following tables present information about our investments in entities that have the characteristics of an investment company (in thousands):
 
February 29, 2020
 
Fair Value (1)
 
Unfunded
Commitments
Equity Long/Short Hedge Funds (2)
$
303,941

 
$

Equity Funds (3)
28,777

 
11,823

Commodity Funds (4)
14,650

 

Multi-asset Funds (5)
542,609

 

Other Funds (6)
160

 

Total
$
890,137

 
$
11,823

 
November 30, 2019
 
Fair Value (1)
 
Unfunded
Commitments
Equity Long/Short Hedge Funds (2)
$
291,593

 
$

Equity Funds (3)
27,952

 
12,108

Commodity Funds (4)
16,025

 

Multi-asset Funds (5)
234,583

 

Other Funds (6)
157

 

Total
$
570,310

 
$
12,108

(1)
Where fair value is calculated based on NAV, fair value has been derived from each of the funds’ capital statements.
(2)
This category includes investments in hedge funds that invest, long and short, primarily in both public and private equity securities in domestic and international markets. At both February 29, 2020 and November 30, 2019, approximately 6% of the fair value of investments in this category are redeemable quarterly with 60 days prior written notice.
(3)
At February 29, 2020 and November 30, 2019, the investments in this category include investments in equity funds that invest in the equity of various U.S. and foreign private companies in the energy, technology, internet service and telecommunication service industries. These investments cannot be redeemed; instead, distributions are received through the liquidation of the underlying assets of the funds which are primarily expected to be liquidated in approximately one to nine years.
(4)
This category includes investments in a hedge fund that invests, long and short, primarily in commodities. Investments in this category are redeemable quarterly with 60 days prior written notice.
(5)
This category includes investments in hedge funds that invest, long and short, primarily in multi-asset securities in domestic and international markets in both the public and private sectors. At February 29, 2020 and November 30, 2019, investments representing approximately 2% and 5%, respectively, of the fair value of investments in this category are redeemable monthly with 30 days prior written notice.
(6)
This category includes investments in a fund that invests in loans secured by a first trust deed on property, domestic and international public high yield debt, private high yield investments, senior bank loans, public leveraged equities, distressed debt and private equity investments and there are no redemption provisions. This category also includes investments in a fund of funds that invests in various private equity funds that are managed by us and have no redemption provisions. Investments in the fund of funds are gradually being liquidated, however, the timing of when the proceeds will be received is uncertain.
Summary of Changes in Fair Value of Financial Assets and Liabilities Classified as Level 3
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the three months ended February 28, 2019 (in thousands):
 
Three Months Ended February 28, 2019
 
 
 
Balance at
November 30, 2018
 
Total gains/losses (realized and unrealized) (1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net transfers into/
(out of) Level 3
 
Balance at February 28, 2019
 
For instruments still held at February 28, 2019, changes in unrealized gains/(losses) included in:
 
earnings (1)
 
other comprehensive income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
51,040

 
$
4,830

 
$
1,410

 
$
(2,411
)
 
$
(66
)
 
$

 
$
(37
)
 
$
54,766

 
$
4,945

 
$

Corporate debt securities
9,484

 
466

 
3,568

 
(3,233
)
 
(834
)
 

 
1,479

 
10,930

 
498

 

CDOs and CLOs
25,815

 
(8,153
)
 
49,201

 
(32,759
)
 

 

 
(1,538
)
 
32,566

 
(3,814
)
 

RMBS
19,603

 
462

 
975

 

 
(27
)
 

 
(50
)
 
20,963

 
494

 

CMBS
10,886

 
136

 
12

 

 
(41
)
 

 
1,827

 
12,820

 
96

 

Other ABS
53,175

 
(2,290
)
 
29,195

 
(30,060
)
 
(12,320
)
 

 
(1,814
)
 
35,886

 
(1,763
)
 

Loans and other receivables
46,985

 
814

 
40,061

 
(27,142
)
 
(1,990
)
 

 
19,323

 
78,051

 
130

 

Investments at fair value
113,831

 
(786
)
 
27,767

 

 

 

 

 
140,812

 
(786
)
 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$

 
$
(2
)
 
$

 
$
80

 
$

 
$

 
$

 
$
78

 
$
2

 
$

Corporate debt securities
522

 
(241
)
 

 

 

 

 
449

 
730

 
241

 

CMBS

 
70

 

 

 

 

 

 
70

 
(70
)
 

Loans
6,376

 
(229
)
 
(1,411
)
 
504

 

 

 
(1,820
)
 
3,420

 
338

 

Net derivatives (2)
21,614

 
(5,348
)
 
(2,804
)
 
3,084

 
169

 

 
12,260

 
28,975

 
3,333

 

Long-term debt
200,745

 
(16,701
)
 

 

 
(5,665
)
 
92,016

 
12,744

 
283,139

 
4,045

 
12,656

(1)
Realized and unrealized gains/losses are reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statement of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the three months ended February 29, 2020 (in thousands):
 
Three Months Ended February 29, 2020
 
 
 
Total gains/losses (realized and unrealized) (1)
 
 
 
 
 
 
 
 
 
Net transfers into/
 (out of) Level 3
 
 
 
For instruments still held at
February 29, 2020, changes in unrealized gains/(losses) included in:
 
Balance at November 30, 2019
 
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
 
Balance at February 29, 2020
 
Earnings (1)
 
Other comprehensive income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
58,301

 
$
(8,195
)
 
$
2,792

 
$
(1,934
)
 
$

 
$

 
$
52,679

 
$
103,643

 
$
(8,206
)
 
$

Corporate debt securities
7,490

 
1,269

 
1,478

 
(503
)
 
(601
)
 

 
15,957

 
25,090

 
879

 

CDOs and CLOs
20,081

 
(2,069
)
 
17,594

 
(17,833
)
 

 

 
3,179

 
20,952

 
(1,823
)
 

RMBS
17,740

 
(280
)
 

 

 
(3
)
 

 
(487
)
 
16,970

 
(250
)
 

CMBS
6,110

 
(306
)
 

 

 
(1,401
)
 

 
(139
)
 
4,264

 
571

 

Other ABS
42,563

 
(4,159
)
 
81,323

 
(72,032
)
 
(1,974
)
 

 
(3,818
)
 
41,903

 
(3,797
)
 

Loans and other receivables
64,240

 
(3,781
)
 
12,940

 
(13,042
)
 
(7,087
)
 

 
1,051

 
54,321

 
(5,109
)
 

Investments at fair value
75,738

 
(20,392
)
 

 
(76
)
 

 

 

 
55,270

 
(20,392
)
 

Securities purchased under agreements to resell
25,000

 

 

 

 
(25,000
)
 

 

 

 

 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
4,487

 
$
291

 
$
(513
)
 
$

 
$

 
$

 
$
10

 
$
4,275

 
$
65

 
$

Corporate debt securities
340

 
(189
)
 
(13,832
)
 
14,079

 
369

 

 

 
767

 
(35
)
 

CMBS
35

 

 

 

 

 

 

 
35

 

 

Loans
9,463

 
1

 
(9,872
)
 
2,781

 

 

 
5,486

 
7,859

 
(1
)
 

Net derivatives (2)
77,168

 
(17,528
)
 
(278
)
 
5,627

 
192

 

 
45,662

 
110,843

 
17,460

 

Long-term debt
480,069

 
(9,016
)
 

 

 

 
128,475

 
(56,065
)
 
543,463

 
(5,590
)
 
14,606

(1)
Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statements of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
Quantitative Information about Significant Unobservable Inputs Used in Level 3 Fair Value Measurements
The tables below present information on the valuation techniques, significant unobservable inputs and their ranges for our financial assets and liabilities, subject to threshold levels related to the market value of the positions held, measured at fair value on a recurring basis with a significant Level 3 balance. The range of unobservable inputs could differ significantly across different firms given the range of products across different firms in the financial services sector. The inputs are not representative of the inputs that could have been used in the valuation of any one financial instrument (i.e., the input used for valuing one financial instrument within a particular class of financial instruments may not be appropriate for valuing other financial instruments within that given class). Additionally, the ranges of inputs presented below should not be construed to represent uncertainty regarding the fair values of our financial instruments; rather, the range of inputs is reflective of the differences in the underlying characteristics of the financial instruments in each category.
For certain categories, we have provided a weighted average of the inputs allocated based on the fair values of the financial instruments comprising the category. We do not believe that the range or weighted average of the inputs is indicative of the reasonableness of uncertainty of our Level 3 fair values. The range and weighted average are driven by the individual financial instruments within each category and their relative distribution in the population. The disclosed inputs when compared with the inputs as disclosed in other periods should not be expected to necessarily be indicative of changes in our estimates of unobservable inputs for a particular financial instrument as the population of financial instruments comprising the category will vary from period to period based on purchases and sales of financial instruments during the period as well as transfers into and out of Level 3 each period.
February 29, 2020
Financial Instruments Owned:
 
Fair Value
(in thousands)
 
Valuation Technique
 
Significant Unobservable Input(s)
 
Input / Range
 
Weighted
Average
Corporate equity securities
 
$
78,543

 
 
 
 
 
 
 
 
 
 
Non-exchange traded securities
 
Market approach
 
Price
 
$1
-
$213
 
$
105

 
 
 
 
 
 
Underlying stock price
 
$3
-
$5
 
$
4

Corporate debt securities
 
$
25,090

 
Market approach
 
Price
 
$69
-
$78
 
$69
 
 
 
 
Scenario Analysis
 
Estimated recovery percentage
 
22
%
-
85%
 
41
%
CDOs and CLOs
 
$
20,952

 
Discounted cash flows
 
Constant prepayment rate
 
20%
 

 
 
 
 
 
 
Constant default rate
 
1
%
-
2%
 
2
%
 
 
 
 
 
 
Loss severity
 
25
%
-
70%
 
28
%
 
 
 
 
 
 
Discount rate/yield
 
13
%
-
30%
 
17
%
RMBS
 
$
16,970

 
Discounted cash flows
 
Cumulative loss rate
 
2%
 

 
 
 
 
 
 
Duration (years)
 
6
 

 
 
 
 
 
 
Discount rate/yield
 
3%
 

CMBS
 
$
4,264

 
Scenario analysis
 
Estimated recovery percentage
 
44%
 

Other ABS
 
$
41,903

 
Discounted cash flows
 
Cumulative loss rate
 
7
%
-
31%
 
14
%
 
 
 
 
 
 
Duration (years)
 
0.5

-
2.8
 
1.6

 
 
 
 
 
 
Discount rate/yield
 
7
%
-
14%
 
11
%
 
 
 
 
Market approach
 
Price
 
$100
 

Loans and other receivables
 
$
52,815

 
Market approach
 
Price
 
$29
-
$101
 
$89
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
63
%
-
100%
 
79
%
Derivatives
 
$
22,216

 
 
 
 
 
 
 
 
 
 
Interest rate swaps
 
 
 
Market approach
 
Basis points upfront
 
0

-
12
 
6

Investments at fair value
 
$
28,927

 
 
 
 
 
 
 
 
 
 
Private equity securities
 
 
 
Market approach
 
Price
 
$8
-
$168
 
$
132

Financial Instruments Sold, Not Yet Purchased:
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
 
$
4,275

 
Market approach
 
Transaction level
 
$1
 

Loans
 
$
5,074

 
Market approach
 
Price
 
$50
 

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
63%
 

Derivatives
 
$
134,087

 
 
 
 
 
 
 
 
 
 
Equity options
 
 
 
Volatility benchmarking
 
Volatility
 
21
%
-
60%
 
42
%
Interest rate swaps
 
 
 
Market approach
 
Basis points upfront
 
0

-
18
 
9

Cross currency swaps
 
 
 
 
 
Basis points upfront
 
2
 

Unfunded commitments
 
 
 
 
 
Price
 
$83
 

Long-term debt
 
 
 
 
 
 
 
 
 
 
 
 
Structured notes
 
$
543,463

 
Market approach
 
Price
 
$90
-
$102
 
$
94

 
 
 
 
 
 
Price
 
€72
-
€105
 
91

November 30, 2019
Financial Instruments Owned
 
Fair Value
(in thousands)
 
Valuation Technique
 
Significant Unobservable Input(s)
 
Input / Range
 
Weighted
Average
Corporate equity securities
 
$
29,017

 
 
 
 
 
 
 
 
 
 
Non-exchange-traded securities
 
 
 
Market approach
 
Price
 
$1
-
$140
 
$
55

 
 
 
 
 
 
Underlying stock price
 
$3
-
$5
 
$
4

Corporate debt securities
 
$
7,490

 
Scenario Analysis
 
Estimated recovery percentage
 
23
%
-
85%
 
46
%
 
 
 
 
 
 
Volatility
 
44%
 

 
 
 
 
 
 
Credit Spread
 
750
 

 
 
 
 
 
 
Underlying stock price
 
£0.4
 

CDOs and CLOs
 
$
20,081

 
Discounted cash flows
 
Constant prepayment rate
 
20%
 

 
 
 
 
 
 
Constant default rate
 
1
%
-
2%
 
2
%
 
 
 
 
 
 
Loss severity
 
25
%
-
37%
 
29
%
 
 
 
 
 
 
Discount rate/yield
 
12
%
-
21%
 
15
%
RMBS
 
$
17,740

 
Discounted cash flows
 
Cumulative loss rate
 
2%
 

 
 
 
 
 
 
Duration (years)
 
6.3
 

 
 
 
 
 
 
Discount rate/yield
 
3%
 

CMBS
 
$
6,110

 
Discounted cash flows
 
Cumulative loss rate
 
7.3%
 

 
 
 
 
 
 
Duration (years)
 
0.2
 

 
 
 
 
 
 
Discount rate/yield
 
85%
 

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
44%
 

Other ABS
 
$
42,563

 
Discounted cash flows
 
Cumulative loss rate
 
7
%
-
31%
 
16
%
 
 
 
 
 
 
Duration (years)
 
0.5

-
3.0
 
1.5

 
 
 
 
 
 
Discount rate/yield
 
7
%
-
15%
 
11
%
Loans and other receivables
 
$
62,734

 
Market approach
 
Price
 
$36
-
$100
 
$
90

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
87
%
-
104%
 
99
%
Derivatives
 
$
13,826

 
 
 
 
 
 
 
 
 
 
Interest rate swaps
 
 
 
Market approach
 
Basis points upfront
 
0

-
16
 
6

Unfunded commitments
 
 
 
 
 
Price
 
$88
 

Equity options
 
 
 
Volatility benchmarking
 
Volatility
 
45%
 

Investments at fair value
 
$
75,736

 
 
 
 
 
 
 
 
 
 
Private equity securities
 
 
 
Market approach
 
Price
 
$8
-
$250
 
$
125

Securities purchased under agreements to resell
 
$
25,000

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Market Approach
 
Spread to 6 month LIBOR
 
500
 

 
 
 
 
 
 
Duration (years)
 
1.5
 

 
 
 
 
 
 
 
 
 
 
 
 
 
Financial Instruments Sold, Not Yet Purchased:
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
 
$
4,487

 
Market approach
 
Transaction level
 
$1
 

Loans
 
$
9,463

 
Market approach
 
Price
 
$50
-
$100
 
$
88

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
1%
 

Derivatives
 
$
92,057

 
 
 
 
 
 
 
 
 
 
Equity options
 
 
 
Volatility benchmarking
 
Volatility
 
21
%
-
61%
 
43
%
Interest rate swaps
 
 
 
Market approach
 
Basis points upfront
 
0

-
22
 
13

Cross currency swaps
 
 
 
 
 
Basis points upfront
 
2
 

Unfunded commitments
 
 
 
 
 
Price
 
$88
 

Long-term debt
 
 
 
 
 
 
 
 
 
 
 
 
Structured notes
 
$
480,069

 
Market approach
 
Price
 
$84
-
$108
 
$
96

 
 
 
 
 
 
Price
 
€74
-
€103
 
€91

Summary of Gains (Losses) Due to Changes in Instrument Specific Credit Risk and Summary of Contractual Principal Exceeds Fair Value for Loans and Other Receivables
The following is a summary of gains (losses) due to changes in instrument specific credit risk on loans, other receivables and debt instruments and gains (losses) due to other changes in fair value on Long-term debt and Short-term borrowings measured at fair value under the fair value option (in thousands):
 
Three Months Ended
 
February 29, 2020
 
February 28, 2019
Financial instruments owned:
 
 
 
Loans and other receivables
$
1,739

 
$
(7,335
)
Financial instruments sold, not yet purchased:
 
 
 
Loans
$
(610
)
 
$

Loan commitments
(661
)
 
79

Long-term debt:
 
 
 
Changes in instrument specific credit risk (1)
$
29,432

 
$
23,483

Other changes in fair value (2)
(37,642
)
 
(10,643
)
Short-term borrowings:
 
 
 
Changes in instrument specific credit risk (1)
$
57

 
$

Other changes in fair value (2)
12

 

(1)
Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statements of Comprehensive Income, net of tax.
(2)
Other changes in fair value are included in Principal transactions revenues in our Consolidated Statements of Earnings.
The following is a summary of the amount by which contractual principal exceeds fair value for loans and other receivables, long-term debt and short-term borrowings measured at fair value under the fair value option (in thousands):
 
February 29, 2020
 
November 30, 2019
Financial instruments owned:
 
 
 
Loans and other receivables (1)
$
1,551,028

 
$
1,546,516

Loans and other receivables on nonaccrual status and/or 90 days or greater past due (1) (2)
267,678

 
197,215

Long-term debt and short-term borrowings
72,301

 
74,408

(1)
Interest income is recognized separately from other changes in fair value and is included in Interest revenues in our Consolidated Statements of Earnings.
(2)
Amounts include loans and other receivables 90 days or greater past due by which contractual principal exceeds fair value of $29.1 million and $22.2 million at February 29, 2020 and November 30, 2019, respectively.